SCHEMBL6403845

SCHEMBL6403845

CC(C)OC[C@@H](CS(=O)(=O)Cc1cnc2ccccc2c1)N(O)C=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.43
HIF1A Q16665 1/20 0.37
EPAS1 Q99814 1/20 0.37
MMP2 P08253 7/20 0.35
MMP13 P45452 6/20 0.35
KDM4E B2RXH2 1/20 0.35
KMT2A Q03164 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
MMP3 P08254 5/20 0.35
ADAM17 P78536 5/20 0.35
MMP9 P14780 5/20 0.35
MMP17 Q9ULZ9 4/20 0.35
CYP1A2 P05177 1/20 0.35
HDAC3 O15379 2/20 0.35
HDAC4 P56524 2/20 0.35
HDAC1 Q13547 2/20 0.35
HDAC7 Q8WUI4 2/20 0.35
HDAC2 Q92769 2/20 0.35
HDAC10 Q969S8 2/20 0.35
HDAC11 Q96DB2 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6606372 1.00 HPGD (0.43) HPGDHIF1AEPAS1MMP2MMP13
SCHEMBL6755588 0.93 HPGD (0.38) HPGDHIF1AEPAS1MMP2MMP13
SCHEMBL6398832 0.91 HPGD (0.36) HPGDHIF1AEPAS1MMP2MMP13
SCHEMBL6399841 0.90 MMP2 (0.40) HIF1AEPAS1MMP2MMP13KDM4E
SCHEMBL6399844 0.90 MMP2 (0.40) HIF1AEPAS1MMP2MMP13KDM4E
SCHEMBL6402218 0.87 MMP2 (0.39) HIF1AEPAS1MMP2MMP13KDM4E
SCHEMBL6402216 0.87 MMP2 (0.39) HIF1AEPAS1MMP2MMP13KDM4E
SCHEMBL6401582 0.86 CYP1A2 (0.38) HIF1AEPAS1KDM4EKMT2ASMN1; SMN2
SCHEMBL6400533 0.86 CYP1A2 (0.38) HIF1AEPAS1KDM4EKMT2ASMN1; SMN2
SCHEMBL6606605 0.86 HPGD (0.38) HPGDHIF1AEPAS1KDM4EKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1289980-B1 BICYCLYL OR HETEROBICYCLYLMETHANESULFONYLAMINO-SUBSTITUTED N-HYDROXYFORMAMIDES SMITHKLINE BEECHAM PLC (GB) 2004-11-17 EP claimed
US-20040024066-A1 Bicyclyl or heterobicyclylmethanesulfonylamino-substituted n-hydroxyformamides SMITHKLINE BEECHAM P.L.C. (GB) 2004-02-05 US claimed
US-20050288376-A1 Bicyclyl or heterobicyclylmethanesulfonylanimo-substituted N-hydroxyformamides SMITHKLINE BEECHAM PLC 2005-12-29 US disclosed
EP-1289980-B1 BICYCLYL OR HETEROBICYCLYLMETHANESULFONYLAMINO-SUBSTITUTED N-HYDROXYFORMAMIDES SMITHKLINE BEECHAM PLC (GB) 2004-11-17 EP disclosed
US-20040024066-A1 Bicyclyl or heterobicyclylmethanesulfonylamino-substituted n-hydroxyformamides SMITHKLINE BEECHAM P.L.C. (GB) 2004-02-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050288376-A1 Bicyclyl or heterobicyclylmethanesulfonylanimo-substituted N-hydroxyformamides CD22, CD2, NEU3 HPGD 1862/4885HIF1A 2197/4885EPAS1 3441/4885
US-20040024066-A1 Bicyclyl or heterobicyclylmethanesulfonylamino-substituted n-hydroxyformamides CD22, CD2, NEU3 HPGD 1564/4885HIF1A 1403/4885EPAS1 3094/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.